Zhen Mahoney
Director, Companion Diagnostics Business Development Agilent Technologies
Seminars
Wednesday 7th October 2026
Panel Discussion: Innovating Global Rx-Dx Trial Pathways Through Strategic & Compliant Co-Development Partnerships to Deliver Harmonized Precision Medicine Solutions
3:10 pm
- When should biomarker evidence trigger CDx development, and how can strategies align with therapeutic goals, clinical endpoints, and regulatory requirements?
- How can organizations build adaptable CDx strategies that support clinical development while addressing regional differences in regulation, testing infrastructure, and clinical practice?
- What partnerships, operating models, and data strategies are needed to embed CDx development across the drug lifecycle and enable coordinated evidence generation and assay readiness?
